Xeris Biopharma (NASDAQ: XERS) saw a more than 7% price gain after a competitor’s FDA setback. Corcept Therapeutics’ relacorilant medication for Cushing’s syndrome was not approved by the FDA due to lack of evidence of effectiveness. Xeris’s Recorlev, approved in 2021, won’t face competition from Corcept. Analysts predict the market for Cushing’s disease could triple by 2030, benefiting Xeris. Despite the positive outlook, Xeris Biopharma was not included in the Motley Fool’s list of top 10 stocks to buy. The Stock Advisor team has a track record of significant returns compared to the S&P 500.

Read more at Nasdaq MarketSite.: Why Xeris Biopharma Stock Zoomed 7% Higher on Wednesday